SK284248B6 - Prášok na použitie v suchom práškovom inhalátore a spôsob jeho výroby - Google Patents

Prášok na použitie v suchom práškovom inhalátore a spôsob jeho výroby Download PDF

Info

Publication number
SK284248B6
SK284248B6 SK1491-2002A SK14912002A SK284248B6 SK 284248 B6 SK284248 B6 SK 284248B6 SK 14912002 A SK14912002 A SK 14912002A SK 284248 B6 SK284248 B6 SK 284248B6
Authority
SK
Slovakia
Prior art keywords
particles
powder according
mixture
magnesium stearate
particle size
Prior art date
Application number
SK1491-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK14912002A3 (sk
Inventor
John Nicholas Staniforth
Morton David Alexander Vodden
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Original Assignee
Chiesi Farmaceutici S. P. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284248(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Chiesi Farmaceutici S. P. A. filed Critical Chiesi Farmaceutici S. P. A.
Publication of SK14912002A3 publication Critical patent/SK14912002A3/sk
Publication of SK284248B6 publication Critical patent/SK284248B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1491-2002A 2000-04-17 2001-04-17 Prášok na použitie v suchom práškovom inhalátore a spôsob jeho výroby SK284248B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
EP00113608 2000-06-27
PCT/EP2001/004338 WO2001078693A2 (en) 2000-04-17 2001-04-17 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets

Publications (2)

Publication Number Publication Date
SK14912002A3 SK14912002A3 (sk) 2003-03-04
SK284248B6 true SK284248B6 (sk) 2004-12-01

Family

ID=26071084

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1491-2002A SK284248B6 (sk) 2000-04-17 2001-04-17 Prášok na použitie v suchom práškovom inhalátore a spôsob jeho výroby

Country Status (32)

Country Link
US (4) US8182791B2 (de)
EP (6) EP1829533B1 (de)
JP (2) JP2003530425A (de)
KR (1) KR20030069047A (de)
CN (1) CN1424909A (de)
AT (5) ATE513542T1 (de)
AU (3) AU4859501A (de)
BR (3) BR0110139A (de)
CA (3) CA2405767C (de)
CY (1) CY1107315T1 (de)
CZ (1) CZ301904B6 (de)
DE (3) DE60123031T2 (de)
DK (3) DK1276472T3 (de)
DZ (1) DZ3315A1 (de)
EE (1) EE05257B1 (de)
ES (3) ES2275669T3 (de)
GB (2) GB2363987A (de)
HU (4) HU230464B1 (de)
IL (1) IL152306A0 (de)
MA (1) MA26892A1 (de)
MX (3) MXPA02010213A (de)
MY (1) MY129384A (de)
NO (4) NO20024971L (de)
NZ (1) NZ521887A (de)
PE (1) PE20011227A1 (de)
PL (3) PL204251B1 (de)
PT (3) PT1719505E (de)
SA (1) SA01220062B1 (de)
SI (2) SI1719505T1 (de)
SK (1) SK284248B6 (de)
TN (1) TNSN01060A1 (de)
WO (3) WO2001078693A2 (de)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
PT1158958E (pt) * 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
CN100551358C (zh) * 2000-06-27 2009-10-21 维克多瑞有限公司 用于药物组合物的颗粒的制备方法
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
AU2002220857A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
AU2002222118A1 (en) † 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US20050191357A1 (en) * 2002-03-20 2005-09-01 Yoshiaki Kawashima Method of manufacturing chemical-containing composite particles
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EA007377B1 (ru) * 2002-08-21 2006-10-27 Нортон Хелткэа Лтд. Композиции для ингаляции
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2004093848A2 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
US7022340B2 (en) 2003-07-25 2006-04-04 Ferring B.V. Pharmaceutical composition as solid dosage form and method for manufacturing thereof
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
AU2004294889B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
AU2005237523A1 (en) * 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2006086270A1 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
JPWO2006095788A1 (ja) * 2005-03-09 2008-08-14 小野薬品工業株式会社 粒子およびその粒子を含有する製剤
CA2603433A1 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (de) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
AU2008214205B2 (en) 2007-02-11 2014-04-24 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
BRPI0814772A2 (pt) 2007-07-21 2015-03-03 Albany Molecular Res Inc Indazóis substituídos por 5-piridinona
EP2222639A1 (de) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryle als pde4-inhibitoren zur behandlung von lungen- und herz-kreislauf-erkrankungen
EP2292089A1 (de) 2008-01-11 2011-03-09 Astellas Pharma Inc. Modelltier mit hodenschmerzen oder beschwerden bei die hoden betreffenden handlungen und häufigem harndrang
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
EP2080508A1 (de) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Trockenpulverformulierung mit einem anticholinergischen Arzneimittel
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2191821A1 (de) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Mikropartikel enthaltend ein Salz von 8-Hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone mit verbesserten Adhesionseigenschaften zur Trockenpulver-Inhalation
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
PL2400950T3 (pl) 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (de) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von kristallinen Partikeln von einem Salz von 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-chinolinon (Carmoterol)
EP2552424B1 (de) 2010-04-01 2018-05-09 Chiesi Farmaceutici S.p.A. Verfahren zur herstellung von trägerteilchen für trockenpulver zur inhalation
ES2658179T3 (es) * 2010-04-21 2018-03-08 Chiesi Farmaceutici S.P.A. Procedimiento para proporcionar partículas con cargas electrostáticas reducidas
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2011152804A2 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
JP2013529606A (ja) 2010-06-22 2013-07-22 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗ムスカリン薬含有乾燥粉末配合物
PE20130601A1 (es) 2010-08-03 2013-05-30 Chiesi Farma Spa Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa
US20130177651A1 (en) * 2010-09-03 2013-07-11 Pharmaterials Limited Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
CN103228273B (zh) 2010-09-29 2017-04-05 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CN103298470B (zh) 2010-09-30 2015-06-17 奇斯药制品公司 硬脂酸镁在吸入用干粉制剂中的用途
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
WO2013109214A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
EP2804583A1 (de) * 2012-01-16 2014-11-26 Mahmut Bilgic Trockenpulverformulierungen mit r-formoterol als wirkstoff
BR112014017481A8 (pt) * 2012-01-25 2021-06-15 Chiesi Farm Spa formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
NZ628072A (en) 2012-03-13 2015-08-28 Respivert Ltd Crystalline pi3 kinase inhibitors
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
SG11201505835QA (en) 2013-01-28 2015-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP2821061B1 (de) * 2013-07-01 2017-12-20 Arven Ilac Sanayi Ve Ticaret A.S. Neue präparate fur atemwege
KR20160029797A (ko) * 2013-07-11 2016-03-15 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
EP3052092A2 (de) * 2013-10-02 2016-08-10 Vectura Limited Verfahren und vorrichtung
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN106102737B (zh) 2013-10-22 2019-06-14 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
EP2957552B1 (de) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterolformulierungen
TR201818680T4 (tr) 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
BR112017008923A2 (pt) 2014-10-31 2017-12-26 Glaxosmithkline Ip Dev Ltd ?formulação em pó?
RU2693201C1 (ru) * 2015-06-23 2019-07-01 Шлюмберже Текнолоджи Б.В. Распознание расклинивающего агента с помощью мобильного устройства
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
HUE050343T2 (hu) 2015-11-16 2020-11-30 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
SI3628331T1 (sl) 2015-11-16 2021-11-30 Chiesi Farmaceutici S.P.A. Postopek za pripravo suhe praškaste formulacije, ki obsega antiholinergik, kortikosteroid in beta-adrenergik
CN108430551A (zh) * 2015-12-24 2018-08-21 菲利普莫里斯生产公司 尼古丁颗粒封壳
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
RU2741427C1 (ru) * 2017-05-11 2021-01-26 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
PL3621590T3 (pl) 2017-05-11 2022-01-17 Chiesi Farmaceutici S.P.A. Sposób wytwarzania preparatu suchego proszku zawierającego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
JP2020531045A (ja) 2017-07-14 2020-11-05 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ１６６抗体およびその使用
CN111107788B (zh) * 2017-07-26 2023-12-19 深圳帧观德芯科技有限公司 具有空间扩展性x射线源的x射线成像系统
JP7079844B2 (ja) 2017-07-27 2022-06-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 高濃度抗ｃ５抗体製剤
WO2019060604A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
CA3105392A1 (en) * 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
AU2019311268A1 (en) 2018-07-27 2021-02-11 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
US20210370007A1 (en) 2018-10-30 2021-12-02 Chiesi Farmaceuticl S.p.A. Apparatus to administer drugs to mechanically ventilated patients
MX2021006968A (es) 2018-12-12 2021-10-13 Kite Pharma Inc Antígeno quimérico y receptores de las células t, y métodos de uso.
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
EP4034079A1 (de) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Neuartige trägerpartikel für trockenpulverformulierungen zur inhalation
EP4138911A1 (de) 2020-04-24 2023-03-01 Millennium Pharmaceuticals, Inc. Anti-cd19-antikörper und verwendungen davon
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
EP4320149A1 (de) 2021-04-09 2024-02-14 Takeda Pharmaceutical Company Limited Gegen komplementfaktor d gerichtete antikörper und verwendungen davon
AR125451A1 (es) 2021-04-26 2023-07-19 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
AR125450A1 (es) 2021-04-26 2023-07-19 Millennium Pharm Inc Anticuerpos anti-adgre2 y usos de los mismos
CA3236038A1 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE59100388D1 (de) 1990-01-29 1993-10-28 Ciba Geigy Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers.
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ES2159524T3 (es) 1992-06-12 2001-10-16 Teijin Ltd Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1019184A1 (de) * 1997-09-30 2000-07-19 Mortimer Technology Holdings Limited Verfahren und vorrichtung zum behandeln von teilchenförmigen material
BR9908771A (pt) * 1998-03-16 2000-12-12 Inhale Therapeutic Syst Processos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano, dispositivo para aumentar a biodisponibilidade de um agente ativo, e, dispositivos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano
SK284889B6 (sk) 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
CN100551358C (zh) * 2000-06-27 2009-10-21 维克多瑞有限公司 用于药物组合物的颗粒的制备方法

Also Published As

Publication number Publication date
EP1276472B1 (de) 2006-12-20
KR20030069047A (ko) 2003-08-25
DK1274406T3 (da) 2007-01-22
EP1276472A2 (de) 2003-01-22
CZ20023437A3 (cs) 2003-02-12
BR0110301A (pt) 2003-12-30
SA01220062B1 (ar) 2006-11-05
DE60131265T2 (de) 2008-03-06
WO2001078695A3 (en) 2002-03-14
MA26892A1 (fr) 2004-12-20
DK1719505T3 (da) 2011-12-05
NO20024973L (no) 2002-12-16
EP1276473A2 (de) 2003-01-22
GB2363988A (en) 2002-01-16
AU4858101A (en) 2001-10-30
NO332025B1 (no) 2012-05-29
PT1276472E (pt) 2007-02-28
DE60125344T2 (de) 2007-07-19
NO20024973D0 (no) 2002-10-16
NO20110885L (no) 2002-12-17
CY1107315T1 (el) 2012-11-21
DK1276472T3 (da) 2007-04-16
MXPA02010218A (es) 2003-05-23
CA2405767A1 (en) 2001-10-25
MY129384A (en) 2007-03-30
DZ3315A1 (fr) 2001-10-25
DE60123031D1 (de) 2006-10-26
CA2406119A1 (en) 2001-10-25
JP2003530425A (ja) 2003-10-14
HUP0300593A2 (hu) 2003-09-29
MXPA02010212A (es) 2004-06-29
WO2001078695A2 (en) 2001-10-25
EE05257B1 (et) 2010-02-15
ES2272473T3 (es) 2007-05-01
CA2406201C (en) 2011-03-22
NZ521887A (en) 2004-06-25
NO20024980D0 (no) 2002-10-16
CN1424909A (zh) 2003-06-18
ATE513542T1 (de) 2011-07-15
US20030180227A1 (en) 2003-09-25
JP2012255035A (ja) 2012-12-27
PT1274406E (pt) 2007-01-31
WO2001078693A2 (en) 2001-10-25
IL152306A0 (en) 2003-05-29
ES2275669T3 (es) 2007-06-16
HUP0300593A3 (en) 2006-07-28
AU2001258343A1 (en) 2001-10-30
EP2272508A2 (de) 2011-01-12
US6884794B2 (en) 2005-04-26
GB0109432D0 (en) 2001-06-06
CA2406201A1 (en) 2001-10-25
US20050201950A1 (en) 2005-09-15
US8182791B2 (en) 2012-05-22
EP2272508A3 (de) 2012-01-18
SK14912002A3 (sk) 2003-03-04
HU229270B1 (en) 2013-10-28
US7223748B2 (en) 2007-05-29
EP1719505A2 (de) 2006-11-08
EP1274406B1 (de) 2006-09-13
EE200200593A (et) 2004-04-15
DE60125344D1 (de) 2007-02-01
CZ301904B6 (cs) 2010-07-28
PL204213B1 (pl) 2009-12-31
WO2001078694A3 (en) 2002-03-14
EP1719505B1 (de) 2011-08-24
ATE348603T1 (de) 2007-01-15
NO20024971L (no) 2002-12-17
AU4859501A (en) 2001-10-30
TNSN01060A1 (fr) 2005-11-10
PL358875A1 (en) 2004-08-23
EP2272508B1 (de) 2020-03-25
US20030175214A1 (en) 2003-09-18
CA2405767C (en) 2011-07-05
PL204251B1 (pl) 2009-12-31
EP1719505A3 (de) 2007-07-18
HUP1300117A2 (en) 2003-07-28
PT1719505E (pt) 2011-10-24
EP1829533B1 (de) 2011-06-22
US20120308613A1 (en) 2012-12-06
DE60123031T2 (de) 2007-03-08
NO342999B1 (no) 2018-09-24
AU784719B2 (en) 2006-06-01
PL359289A1 (en) 2004-08-23
MXPA02010213A (es) 2005-07-01
EP1276473B1 (de) 2007-11-07
CA2406119C (en) 2009-07-07
ATE377416T1 (de) 2007-11-15
ATE521340T1 (de) 2011-09-15
WO2001078694A2 (en) 2001-10-25
GB2363987A (en) 2002-01-16
BR0110141A (pt) 2003-01-28
EP1829533A3 (de) 2007-10-31
WO2001078693A3 (en) 2002-01-17
PL358640A1 (en) 2004-08-09
SI1274406T1 (sl) 2007-02-28
EP1274406A2 (de) 2003-01-15
SI1719505T1 (sl) 2011-12-30
NO20024980L (no) 2002-12-17
NO20024971D0 (no) 2002-10-16
HU229797B1 (en) 2014-07-28
HU230464B1 (hu) 2016-07-28
HUP0300490A2 (en) 2003-07-28
GB0109431D0 (en) 2001-06-06
DE60131265D1 (de) 2007-12-20
NO336687B1 (no) 2015-10-19
EP1829533A2 (de) 2007-09-05
ATE339195T1 (de) 2006-10-15
PE20011227A1 (es) 2002-01-07
HUP0300499A2 (en) 2003-07-28
ES2292576T3 (es) 2008-03-16
BR0110139A (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
US7223748B2 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US6641844B1 (en) Modified carrier particles for use in dry powder inhalers
US9566239B2 (en) Pharmaceutical formulations for dry powder inhalers
US6780508B1 (en) Powder particles with smooth surface for use in inhalation therapy

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20210417